Eli Lilly and Co
Change company Symbol lookup
Select an option...
LLY Eli Lilly and Co
FNMA Federal National Mortgage Association
MPW Medical Properties Trust Inc
PSXP Phillips 66 Partners LP
EQ Equillium Inc
TSLA Tesla Inc
OPK OPKO Health Inc
PNW Pinnacle West Capital Corp
ROLL RBC Bearings Inc
GLAD Gladstone Capital Corp
Go

Health Care : Pharmaceuticals | Large Cap Blend
Company profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Closing Price
$130.46
Day's Change
-2.09 (-1.58%)
Bid
--
Ask
--
B/A Size
--
Day's High
133.11
Day's Low
129.21
Volume
(Average)
Volume:
4,336,046

10-day average volume:
4,039,002
4,336,046

Display:

Providers:

UpdateCancel
6 providers
Yesterday's News, October 30, 2020
Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata

Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib (marketed as OLUMIANT(R)) will be presented at the annual Fall Clinical Dermatology meeting taking place virtually October 29-November 1, 2020. The...(PR Newswire)

October 28, 2020
Data for Lilly's bamlanivimab (LY-CoV555) in COVID-19 outpatients published in New England Journal of Medicine

The New England Journal of Medicine has published data from the monotherapy arms of BLAZE-1, a Phase 2 study assessing the efficacy and safety of Eli Lilly and Company's (NYSE: LLY) bamlanivimab (LY-CoV555) - a neutralizing antibody - in the...(PR Newswire)

Lilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19

Eli Lilly and Company (NYSE: LLY) announced today an initial agreement with the U.S. government to supply 300,000 vials of bamlanivimab (LY-CoV555) 700 mg, an investigational neutralizing antibody, for $375 million. The U.S. government will accept...(PR Newswire)

October 27, 2020
Lilly Reports Third-Quarter Financial Results, Updates Guidance

Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2020. Certain financial information for 2020 and 2019 is presented on both a reported and a non-GAAP basis. Some numbers in this press release may not add...(PR Newswire)

MBX Biosciences Appoints James Cornelius to its Board of Directors

MBX Biosciences, a drug discovery company focused in rare endocrine diseases, today announced the appointment of James Cornelius to its board of directors. "Jim Cornelius is among the most accomplished global biopharmaceutical executives, and he is...(BusinessWire)

October 26, 2020
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eli Lilly and Company - LLY

Pomerantz LLP is investigating claims on behalf of investors of Eli Lilly and Company ("Eli Lilly" or the "Company") (NYSE: LLY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. (Globe Newswire)

October 23, 2020
New Jardiance(R) findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status

Findings from a new exploratory sub-analysis of the EMPEROR-Reduced phase III trial showed that Jardiance(R) (empagliflozin) reduced the risk of adverse cardiovascular and kidney events in adults with heart failure with reduced ejection fraction...(PR Newswire)

October 22, 2020
In Pursuit of the Elusive Drug -- the Billion-Dollar Blockbuster

Enormous amounts of money exchange hands in the big pharma space as companies merge and are acquired -- all in search of the next blockbuster drug. While the discovery of a blockbuster drug, or a drug that generates more than $1 billion in sales per...(PR Newswire)

October 21, 2020
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Eli Lilly and Company and Encourages Investors with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - October 21, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Eli Lilly and Company ("Eli Lilly" or "the...(Newsfile)

October 20, 2020
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eli Lilly and Company - LLY

Pomerantz LLP is investigating claims on behalf of investors of Eli Lilly and Company ("Eli Lilly" or the "Company") (NYSE: LLY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. (PR Newswire)

ELI LILLY AND COMPANY ALERT: Bragar Eagel & Squire, P.C. is Investigating Eli Lilly and Company on Behalf of Eli Lilly Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Eli Lilly and Company (NYSE: LLY) on behalf of Eli Lilly stockholders. Our investigation concerns whether Eli Lilly has...(Globe Newswire)

The Law Offices of Frank R. Cruz Continues Its Investigation of Eli Lilly and Company (LLY) on Behalf of Investors

The Law Offices of Frank R. Cruz continues its investigation of Eli Lilly and Company ("Eli Lilly" or the "Company") (NYSE: LLY) on behalf of investors concerning the Company's possible violations of federal securities laws. (BusinessWire)

Psychedelics Could Become the Next Health and Wellness Trend

Research continues to mount on the health benefits of psychedelic drugs like psilocybin and loosening government restrictions are completely changing the way the world views psychedelics. What was once reserved for teenagers tripping out in their...(PR Newswire)

The 5th Annual Companion Diagnostics Forum on Oct 27-28 gathers scientists, clinicians, regulators and industry professionals for two days of web-based presentations

The 5th Annual Companion Diagnostics Forum will take place Tuesday and Wednesday, October 27-28, 2020. Register at http://companiondiagnosticsforum.com. "The online Companion Diagnostics Forum is focused on the need for Companion Diagnostics to grow...(PR Newswire)

October 19, 2020
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Eli Lilly and Company (LLY) on Behalf of Investors

Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, continues its investigation on behalf of Eli Lilly and Company ("Eli Lilly" or the "Company") (NYSE: LLY) investors concerning the Company's possible violations...(BusinessWire)

Lilly Declares Fourth-Quarter 2020 Dividend

The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2020 of $0.74 per share on outstanding common stock. The dividend is payable December 10, 2020, to shareholders of record at the close of...(PR Newswire)

October 18, 2020
Eli Lilly Shareholder Notice: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Eli Lilly and Company To Contact The Firm

New York, New York--(Newsfile Corp. - October 18, 2020) - Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential claims against Eli Lilly and Company ("Eli Lilly" or the...(Newsfile)

October 16, 2020
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Eli Lilly and Company and Encourages Investors with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - October 16, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Eli Lilly and Company ("Eli Lilly" or "the...(Newsfile)

October 15, 2020
Eli Lilly Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Eli Lilly and Company To Contact The Firm

New York, New York--(Newsfile Corp. - October 15, 2020) - Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential claims against Eli Lilly and Company ("Eli Lilly" or the...(Newsfile)

ELI LILLY AND COMPANY ALERT: Bragar Eagel & Squire, P.C. is Investigating Eli Lilly and Company on Behalf of Eli Lilly Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Eli Lilly and Company (NYSE: LLY) on behalf of Eli Lilly stockholders. Our investigation concerns whether Eli Lilly has...(Globe Newswire)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.